Skip to main content
SpringerLink
Log in

Stellungnahme von BVA, DOG und RG zur intravitrealen Therapie des visusmindernden Makulaödems bei retinalem Venenverschluss

Therapeutische Strategien, Stand 24.04.2018

Statement of the Professional Association of Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the Retinological Society (RG) on intravitreal treatment of vision-reducing macular edema by retinal vein occlusion

Treatment strategies, status 24 April 2018

  • Leitlinien, Stellungnahmen und Empfehlungen
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

Verwendete Literatur

  1. Deutsche Ophthalmologische Gesellschaft, Retinologische Gesellschaft, Berufsverband der Augenärzte Deutschlands (2010) Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie des Makulaödems beim retinalen Venenverschluss. Ophthalmologe 107:583–596

    Article  Google Scholar 

  2. Ehlers JP, Kim SJ, Yeh S, Thorne JE, Mruthyunjaya P, Schoenberger SD et al (2017) Therapies for macular edema associated with branch retinal vein occlusion: a report by the American academy of ophthalmology. Ophthalmology 124(9):1412–1423

    Article  PubMed  Google Scholar 

  3. Berger AR, Cruess AF, Altomare F, Chaudhary V, Colleaux K, Greve M et al (2015) Optimal treatment of retinal vein occlusion: Canadian expert consensus. Ophthalmologica 234(1):6–25

    Article  PubMed  Google Scholar 

  4. Pulido JS, Flaxel CJ, Adelman RA, Hyman L, Folk JC, Olsen TW (2016) Retinal vein occlusions preferred practice pattern(®) guidelines. Ophthalmology 123(1):P182–P208

    Article  PubMed  Google Scholar 

  5. Pielen A, Feltgen N, Isserstedt C, Callizo J, Junker B, Schmucker C (2013) Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS ONE 8(10):e78538

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Mir TA, Kherani S, Hafiz G, Scott AW, Zimmer-Galler I, Wenick AS et al (2016) Changes in retinal Nonperfusion associated with suppression of vascular Endothelial growth factor in retinal vein occlusion. Ophthalmology 123(3):625–634

    Article  PubMed  Google Scholar 

  7. Clark WL, Boyer DS, Heier JS, Brown DM, Haller JA, Vitti R et al (2016) Intravitreal Aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 123(2):330–336

    Article  PubMed  Google Scholar 

  8. Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL et al (2014) Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial. Retina (Philadelphia, Pa) 34(9):1728–1735

    Article  CAS  Google Scholar 

  9. Thach AB, Yau L, Hoang C, Tuomi L (2014) Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trials. Ophthalmology 121(5):1059–1066

    Article  PubMed  Google Scholar 

  10. Hattenbach L‑O, Feltgen N, Bertelmann T, Schmitz-Valckenberg S, Berk H, Eter N et al (2018) Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B). Acta Ophthalmol (copenh) 96(1):e10–e8

    Article  CAS  Google Scholar 

  11. Hoerauf H, Feltgen N, Weiss C, Paulus E‑M, Schmitz-Valckenberg S, Pielen A et al (2016) Clinical efficacy and safety of Ranibizumab versus Dexamethasone for central retinal vein occlusion (COMRADE C): a European label study. Am J Ophthalmol 169:258–267

    Article  CAS  PubMed  Google Scholar 

  12. Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC et al (2017) Effect of Bevacizumab vs Aflibercept on visual acuity among patients with macular edema Due to central retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA 317(20):2072–2087

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH et al (2015) A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. Br J Ophthalmol 99(7):954–959

    Article  PubMed  Google Scholar 

  14. Gado AS, Macky TA (2014) Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. Clin Exp Ophthalmol 42(7):650–655

    Article  PubMed  Google Scholar 

  15. Lotfy A, Solaiman KAM, Abdelrahman A, Samir A (2017) EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Retina (Philadelphia, Pa). https://doi.org/10.1097/iae.0000000000001782

    Article  Google Scholar 

  16. Rajagopal R, Shah GK, Blinder KJ, Altaweel M, Eliott D, Wee R et al (2015) Bevacizumab versus Ranibizumab in the treatment of macular edema Due to retinal vein occlusion: 6‑month results of the CRAVE study. Ophthalmic Surg lasers imaging. Retina 46(8):844–850

    Google Scholar 

  17. Bandello F, Augustin A, Tufail A, Leaback R (2018) A 12-month, multicenter, parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion. Eur J Ophthalmol. https://doi.org/10.1177/1120672117750058

    Article  PubMed  PubMed Central  Google Scholar 

  18. Yoon YH, Kim JW, Lee JY, Kim IT, Kang SW, Yu HG et al (2018) Dexamethasone Intravitreal implant for early treatment and retreatment of macular edema related to branch retinal vein occlusion: the Multicenter COBALT study. Ophthalmologica 240(2):81–89. https://doi.org/10.1159/000487547

    Article  CAS  PubMed  Google Scholar 

  19. Goñi FJ, Stalmans I, Denis P, Nordmann J‑P, Taylor S, Diestelhorst M et al (2016) Elevated Intraocular pressure after Intravitreal steroid injection in diabetic macular edema: monitoring and management. Ophthalmol Ther 5(1):47–61

    Article  PubMed Central  PubMed  Google Scholar 

  20. Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ (2017) Trends of anti-vascular Endothelial growth factor use in ophthalmology among privately insured and medicare advantage patients. Ophthalmology 124(3):352–358

    Article  PubMed  Google Scholar 

  21. Wang MD, Jeng-Miller KW, Feng HL, Prenner JL, Fine HF, Shah SP (2016) Retina specialists treating cystoid macular oedema secondary to retinal vein occlusion recommend different treatments for patients than they would choose for themselves. Br J Ophthalmol 100(10):1332–1336

    Article  PubMed  Google Scholar 

  22. Mishra SK, Gupta A, Patyal S, Kumar S, Raji K, Singh A et al (2018) Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety. Int J Retina Vitreous 4(1):13. https://doi.org/10.1186/s40942-018-0114-2

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kube T, Sutter M, Trittler R, Feltgen N, Hansen LL, Agostini HT (2006) Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone. Graefes Arch Clin Exp Ophthalmol 244:1385–1390

    Article  CAS  PubMed  Google Scholar 

  24. Bressler NM (2017) Treatment of macular edema Due to central retinal vein occlusion: another score for repackaged Bevacizumab. JAMA 317(20):2067–2069. https://doi.org/10.1001/jama.2017.5899

    Article  PubMed  Google Scholar 

  25. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N et al (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118(10):2041–2049

    Article  PubMed  Google Scholar 

  26. Brown DM, Campochiaro PA, Bhisitkul RB, Ho AC, Gray S, Saroj N et al (2011) Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 118(8):1594–1602

    Article  PubMed  Google Scholar 

  27. Campochiaro PA, Wykoff CC, Singer M, Johnson R, Marcus D, Yau L et al (2014) Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE study. Ophthalmology 121(12):2432–2442

    Article  PubMed  Google Scholar 

  28. Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I, Priglinger S et al (2016) Individualized stabilization criteria-driven Ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology 123(6):1332–1344

    Article  PubMed  Google Scholar 

  29. Korobelnik J‑F, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U et al (2014) Intravitreal Aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase 3 GALILEO study. Ophthalmology 121(1):202–208

    Article  PubMed  Google Scholar 

  30. Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ et al (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1‑year results from the phase 3 COPERNICUS study. Am J Ophthalmol 155(3):429–437

    Article  CAS  PubMed  Google Scholar 

  31. Ziemssen F, Bertelmann T, Hufenbach U, Scheffler M, Liakopoulos S, Schmitz-Valckenberg S (2016) Delayed treatment initiation of more than 2 weeks : Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study). Ophthalmologe 113(2):143–151

    Article  CAS  PubMed  Google Scholar 

  32. Dirani A, Mantel I, Ambresin A (2015) Recurrent macular edema in central retinal vein occlusion treated with Intravitreal Ranibizumab using a modified treat and extend regimen. Klin Monbl Augenheilkd 232(4):538–541

    Article  CAS  PubMed  Google Scholar 

  33. Freund KB, Korobelnik J‑F, Devenyi R, Framme C, Galic J, Herbert E et al (2015) TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: a literature review and consensus recommendations. Retina (Philadelphia, Pa) 35(8):1489–1506

    Article  CAS  Google Scholar 

  34. Hufendiek K, Pielen A, Framme C (2017) Injektionsstrategien bei der Anwendung intravitrealer VEGF-Inhibitoren: „Pro Re Nata versus Treat and Extend“. Klin Monbl Augenheilkd 235(8):930–939. https://doi.org/10.1055/s-0042-122340

    Article  PubMed  Google Scholar 

  35. Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J, Tadayoni R et al (2016) Individualized Ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology 123(5):1101–1111

    Article  PubMed  Google Scholar 

  36. Wai KM, Khan M, Srivastava S, Rachitskaya A, Silva FQ, Deasy R et al (2017) Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice. Br J Ophthalmol 101(5):574–579

    Article  PubMed  Google Scholar 

  37. Wecker T, Ehlken C, Bühler A, Lange C, Agostini H, Böhringer D et al (2017) Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol 101(3):353–359

    PubMed  Google Scholar 

  38. Eter N, Mohr A, Wachtlin J, Feltgen N, Shirlaw A, Leaback R et al (2017) Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial. Graefes Arch Clin Exp Ophthalmol 255(1):77–87

    Article  CAS  PubMed  Google Scholar 

  39. Callizo J, Schmitz-Valckenberg S, Spital G, Liakopoulos S, Bertelmann T, Voegeler J et al (2017) Erläuterung des Behandlungserfolges bei RVV-Patienten mit VEGF Inhibition in einer prospektiven, nicht-interventionellen Studie über 12 Monate. DOG, Berlin (Retina: Intravitreale Injektionen)

    Google Scholar 

  40. Feltgen N, Ziemssen F, Spital G, Liakopoulos S, Voegeler J, Koch M et al (2017) Analysis of baseline factors affecting outcome of RVO patients to ranibizumab therapy in a prospective, non-interventional trial (OCEAN study). EURETINA, Barcelona (Vascular Diseases and Diabetc Retinopathy)

    Google Scholar 

  41. Korobelnik J‑F, Kodjikian L, Delcourt C, Gualino V, Leaback R, Pinchinat S et al (2016) Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France. Graefes Arch Clin Exp Ophthalmol 254(12):2307–2318

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M et al (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 127:1101–1114 (Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5)

    Article  PubMed Central  PubMed  Google Scholar 

  43. Tadayoni R, Waldstein SM, Boscia F, Gerding H, Gekkieva M, Barnes E et al (2017) Sustained benefits of Ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology 124(12):1778–1787

    Article  PubMed  Google Scholar 

  44. Pielen A, Mirshahi A, Feltgen N, Lorenz K, Korb C, Junker B et al (2015) Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES): six-month results of a prospective randomized clinical trial. Acta Ophthalmol (copenh) 93(1):e29–e37

    Article  CAS  Google Scholar 

  45. Leitritz MA, Gelisken F, Ziemssen F, Szurman P, Bartz-Schmidt KU, Jaissle GB (2013) Grid laser photocoagulation for macular oedema due to branch retinal vein occlusion in the age of bevacizumab? Results of a prospective study with crossover design. Br J Ophthalmol 97(2):215–219

    Article  PubMed  Google Scholar 

  46. Lam FC, Chia SN, Lee RMH (2015) Macular grid laser photocoagulation for branch retinal vein occlusion. Cochrane Database Syst Rev 11(5):CD8732. https://doi.org/10.1002/14651858.cd008732.pub2

    Article  Google Scholar 

  47. Donati S, Barosi P, Bianchi M, Al Oum M, Azzolini C (2012) Combined intravitreal bevacizumab and grid laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Eur J Ophthalmol 22(4):607–614

    Article  PubMed  Google Scholar 

  48. Russo V, Barone A, Conte E, Prascina F, Stella A, Noci ND (2009) Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina (Philadelphia, Pa) 29:511–515

    Article  Google Scholar 

  49. Tan MH, McAllister IL, Gillies ME, Verma N, Banerjee G, Smithies LA et al (2014) Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol 157(1):237–247

    Article  CAS  PubMed  Google Scholar 

  50. The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98(3):271–282. https://doi.org/10.1016/0002-9394(84)90316-7

    Article  Google Scholar 

  51. Tomiyasu T, Hirano Y, Yoshida M, Suzuki N, Nishiyama T, Uemura A et al (2016) Microaneurysms cause refractory macular edema in branch retinal vein occlusion. Sci Rep 6(1):29445. https://doi.org/10.1038/srep29445

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Gozawa M, Takamura Y, Miyake S, Matsumura T, Morioka M, Yamada Y et al (2017) Photocoagulation of the retinal Nonperfusion area prevents the expression of the vascular Endothelial growth factor in an animal model. Invest Ophthalmol Vis Sci 58(13):5946–5953

    Article  PubMed  Google Scholar 

  53. Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I et al (2015) Scatter Photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. Ophthalmology 122(7):1426–1437

    Article  PubMed  Google Scholar 

  54. Wykoff CC, Ou WC, Wang R, Brown DM, Cone C, Zamora D et al (2017) Peripheral laser for recalcitrant macular edema owing to retinal vein occlusion: the WAVE trial. Ophthalmology 124(6):919–921

    Article  PubMed  Google Scholar 

  55. Rehak M, Tilgner E, Franke A, Rauscher FG, Brosteanu O, Wiedemann P (2014) Early peripheral laser photocoagulation of nonperfused retina improves vision in patients with central retinal vein occlusion (Results of a proof of concept study). Graefes Arch Clin Exp Ophthalmol 252(5):745–752

    Article  PubMed  Google Scholar 

  56. Tomomatsu Y, Tomomatsu T, Takamura Y, Gozawa M, Arimura S, Takihara Y et al (2016) Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions. Acta Ophthalmol (copenh) 94(3):e225–e230

    Article  CAS  Google Scholar 

Weiterführende Literatur

  1. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG et al (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119:802–809

    Article  PubMed  Google Scholar 

  2. Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R et al (2015) Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 122(3):538–544

    Article  PubMed  Google Scholar 

  3. Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J et al (2011) Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118:2453–2460

    Article  PubMed  Google Scholar 

  4. Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J et al (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117:1134–1146

    Article  PubMed  Google Scholar 

  5. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al (2010) Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117(6):1124–1133

    Article  PubMed  Google Scholar 

  6. Kreutzer TC, Wolf A, Dirisamer M, Strauss RW, Foerster P, Feltgen N et al (2015) Intravitreal ranibizumab versus isovolemic hemodilution in the treatment of macular edema secondary to central retinal vein occlusion: twelve-month results of a prospective, randomized, multicenter trial. Ophthalmologica 233(1):8–17

    Article  CAS  PubMed  Google Scholar 

  7. Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ et al (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 121(7):1414–1420

    Article  PubMed  Google Scholar 

  8. Epstein DLJ, Algvere PV, von Wendt G, Seregard S, Kvanta A (2012) Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 119(6):1184–1189

    Article  PubMed  Google Scholar 

  9. Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A (2012) Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 119(12):2587–2591

    Article  PubMed  Google Scholar 

  10. Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH et al (2010) Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 150(3):310–314

    Article  CAS  PubMed  Google Scholar 

Download references

Redaktionskomitee

Prof. Dr. Hansjürgen Agostini, Freiburg

Prof. Dr. Bernd Bertram, Aachen

Prof. Dr. Norbert Bornfeld, Essen

Dr. Martin Bresgen, Köln

Prof. Dr. Nicolas Feltgen, Göttingen (federführend)

Prof. Dr. Lars-Olaf Hattenbach, Ludwigshafen

Prof. Dr. Horst Helbig, Regensburg

Prof. Dr. Hans Hoerauf, Göttingen

Prof. Dr. Frank G. Holz, Bonn

Prof. Dr. Gabriele E. Lang, Ulm

Prof. Dr. Daniel Pauleikhoff, Münster

Dr. Amelie Pielen, Hannover

PD Dr. Matus Rehak, Leipzig

Prof. Dr. Focke Ziemssen, Tübingen

Author information

Authors and Affiliations

    Consortia

    Berufsverband der Augenärzte Deutschlands e. V. (BVA)

    Deutsche Ophthalmologische Gesellschaft (DOG)

    Retinologische Gesellschaft e. V. (RG)

    Ethics declarations

    Interessenkonflikt

    Siehe Tab. 1 im Anhang.

    Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

    Additional information

    Diese Leitlinie erscheint zeitgleich in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, Georg Thieme Verlag, Stuttgart.

    Die Literatur zum Zusatzmaterial Online finden Sie am Ende dieses Beitrags unter „Weiterführende Literatur“.

    Caption Electronic Supplementary Material

    347_2018_775_MOESM1_ESM.pdf

    Datentabelle zur Stellungnahme von BVA, DOG und RG zur Intravitrealen Therapie des visusmindernden Makulaödems bei retinalem Venenverschluss

    Anhang

    Anhang

     

    Tab. 1 Tabellarische Zusammenfassung der Erklärungen über Interessenkonflikte. Stellungnahme intravitreale Therapie des visusmindernden Makulaödems bei retinalem Venenverschluss. Therapeutische Strategien
    Full size table

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Berufsverband der Augenärzte Deutschlands e. V. (BVA)., Deutsche Ophthalmologische Gesellschaft (DOG). & Retinologische Gesellschaft e. V. (RG). Stellungnahme von BVA, DOG und RG zur intravitrealen Therapie des visusmindernden Makulaödems bei retinalem Venenverschluss. Ophthalmologe 115, 842–854 (2018). https://doi.org/10.1007/s00347-018-0775-0

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s00347-018-0775-0

    Search

    Navigation